Published in Circulation on February 10, 2004
e-NOBORI Observational Registry of Nobori DES (e-NOBORI) | NCT01261273
A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ (2007) 2.35
Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart (2005) 1.45
Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual? Catheter Cardiovasc Interv (2008) 1.39
Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial. JACC Cardiovasc Interv (2009) 1.38
Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution. J Control Release (2007) 1.29
Neointimal hyperplasia associated with synthetic hemodialysis grafts. Kidney Int (2008) 1.18
Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1. J Biol Chem (2010) 1.14
What reimbursement for coronary revascularization with drug-eluting stents? Eur J Health Econ (2004) 1.09
Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes. Heart (2006) 1.07
Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler Thromb Vasc Biol (2008) 1.07
Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study. Heart (2005) 1.06
High prevalence of undiagnosed impaired glucose regulation and diabetes mellitus in patients scheduled for an elective coronary angiography. Clin Res Cardiol (2006) 0.97
Thoracic aortic disease in tuberous sclerosis complex: molecular pathogenesis and potential therapies in Tsc2+/- mice. Hum Mol Genet (2010) 0.96
Subconjunctival sirolimus in the treatment of diabetic macular edema. Graefes Arch Clin Exp Ophthalmol (2011) 0.95
Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels (2011) 0.94
ALOX5AP variants are associated with in-stent restenosis after percutaneous coronary intervention. Atherosclerosis (2008) 0.92
High-definition computed tomography for coronary artery stent imaging: a phantom study. Korean J Radiol (2011) 0.91
Long-term outcomes of patients receiving drug-eluting stents. CMAJ (2008) 0.90
Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br J Clin Pharmacol (2008) 0.90
'Miracle stents'--a future without restenosis. Mcgill J Med (2007) 0.89
Are "treatment" bare metal stents superior to "control" bare metal stents? A meta-analytic approach. Am Heart J (2008) 0.87
Improvement of in-stent lumen measurement accuracy with new high-definition CT in a phantom model: comparison with conventional 64-detector row CT. Int J Cardiovasc Imaging (2011) 0.86
Small coronary vessel angioplasty: outcomes and technical considerations. Vasc Health Risk Manag (2010) 0.83
Coronary artery overexpansion increases neointimal hyperplasia after stent placement in a porcine model. Heart (2007) 0.81
Systemic exposure of sirolimus after coronary stent implantation in patients with de novo coronary lesions: Supralimus-Core® pharmacokinetic study. Indian Heart J (2012) 0.81
Drug-eluting stents ameliorate pulmonary vein stenotic changes in pigs in vivo. Pediatr Cardiol (2010) 0.80
Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease. Clin J Am Soc Nephrol (2008) 0.80
CT virtual endoscopy and 3D stereoscopic visualisation in the evaluation of coronary stenting. Biomed Imaging Interv J (2009) 0.80
Plaque Tissue Components Obtained from De Novo Lesions may Predict Restenosis after Directional Coronary Atherectomy. Ann Vasc Dis (2010) 0.80
Evaluation of prolonged safety and efficacy of biodegradable polymer coated sirolimus-eluting coronary stent system: 1-year outcomes of the INDOLIMUS Registry. Cardiovasc Diagn Ther (2015) 0.78
Short- and long-term outcomes of single bare metal stent versus drug eluting stent in nondiabetic patients with a simple de novo lesion in the middle and large vessel. J Transl Med (2008) 0.78
Drug-eluting stents in the management of peripheral arterial disease. Vasc Health Risk Manag (2008) 0.78
Evaluation of long-term clinical and health service outcomes following coronary artery revascularisation in Western Australia (WACARP): a population-based cohort study protocol. BMJ Open (2014) 0.78
Lesion length impacts long term outcomes of drug-eluting stents and bare metal stents differently. PLoS One (2013) 0.78
Assessment of the relation between IVUS measurements and clinical outcome in elderly patients after sirolimus-eluting stent implantation for de novo coronary lesions. Int J Cardiovasc Imaging (2012) 0.77
Comparison of the safety and efficacy of biodegradable polymer drug-eluting stents versus durable polymer drug-eluting stents: a meta-analysis. Eur J Med Res (2015) 0.77
Impact of Insulin Resistance on Neointimal Tissue Proliferation after 2nd-Generation Drug-Eluting Stent Implantation. Tex Heart Inst J (2015) 0.77
A meta-analysis of clinical trials of paclitaxel- and sirolimus-eluting stents in patients with obstructive coronary artery disease. Br J Clin Pharmacol (2005) 0.77
Sera from patients with diabetes do not alter the effect of mammalian target of rapamycin inhibition on smooth muscle cell proliferation. J Cardiovasc Pharmacol (2009) 0.77
Are drug eluting stents really worth the money? Heart (2005) 0.77
Endovascular stent graft repair of abdominal aortic aneurysms: Current status and future directions. World J Radiol (2009) 0.76
Stent choice and the hidden consequences of cost savings. Nat Rev Cardiol (2012) 0.76
Update on stents: recent studies on the TAXUS stent system in small vessels. Vasc Health Risk Manag (2007) 0.76
Drug-eluting coronary stents - focus on improved patient outcomes. Patient Relat Outcome Meas (2011) 0.76
A clinical evaluation of the ProNOVA XR polymer-free sirolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions (EURONOVA XR I study). Indian Heart J (2013) 0.76
Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI). Vasc Health Risk Manag (2006) 0.75
Multiple outcomes and multiple sources of evidence: best statistical practices. Circ Cardiovasc Qual Outcomes (2011) 0.75
Comparative Study between Perfusion Changes and Positive Findings on Coronary Flow Reserve. Arq Bras Cardiol (2016) 0.75
An Egr-1-specific DNAzyme regulates Egr-1 and proliferating cell nuclear antigen expression in rat vascular smooth muscle cells. Exp Ther Med (2013) 0.75
Rapamycin regulates the expression and activity of Krüppel-like transcription factor 2 in human umbilical vein endothelial cells. PLoS One (2012) 0.75
Cobalt-chromium stents in long lesions of large vessels: clinical and angiographic results. Tex Heart Inst J (2011) 0.75
Nine-Months Clinical Outcome of Biodegradable Polymer Coated Sirolimus-eluting Stent System: A Multi-Centre "Real-World" Experience. J Clin Diagn Res (2015) 0.75
Prevention of stent thrombosis: challenges and solutions. Vasc Health Risk Manag (2015) 0.75
Macromolecular approaches to prevent thrombosis and intimal hyperplasia following percutaneous coronary intervention. Biomacromolecules (2014) 0.75
Influence of increased epicardial adipose tissue volume on 1-year in-stent restenosis in patients who received coronary stent implantation. J Geriatr Cardiol (2016) 0.75
Association of the Endothelial Nitric Oxide Synthase Gene T786C Polymorphism with In-Stent Restenosis in Chinese Han Patients with Coronary Artery Disease Treated with Drug-Eluting Stent. PLoS One (2017) 0.75
Reduction of neointimal hyperplasia in porcine coronary arteries by 2-deoxy-D-glucose. Clin Res Cardiol (2009) 0.75
Impact of smoking on health-related quality of Life after percutaneous coronary intervention treated with drug-eluting stents: a longitudinal observational study. Health Qual Life Outcomes (2017) 0.75
A higher colour grade yellow plaque was detected at one year after implantation of an everolimus-eluting stent than after a zotarolimus-eluting stent. Heart Asia (2013) 0.75
Constant maintenance of an alternative route of coronary flow in radical surgery for gastric cancer following coronary artery bypass grafting involving the right gastroepiploic artery: a case report. J Surg Case Rep (2017) 0.75
Influence of a dexamethasone-eluting covered stent on tissue reaction: an experimental study in a canine bronchial model. Eur Radiol (2005) 0.75
Coronary in-stent restenosis: predisposing clinical and stent-related factors, diagnostic performance and analyses of inaccuracies in 320-row computed tomography angiography. Int J Cardiovasc Imaging (2016) 0.75
[Revascularization of coronary artery disease in diabetes mellitus]. Wien Med Wochenschr (2010) 0.75
Angiographic and clinical outcome for the treatment of in-stent restenosis with sirolimus-eluting stent compared to vascular brachytherapy. Z Kardiol (2005) 0.75
Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med (2010) 22.04
Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med (2010) 17.57
Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med (2011) 15.70
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med (2004) 12.58
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med (2004) 11.86
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation (2002) 8.51
Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA (2012) 6.96
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77
Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med (2015) 6.28
Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med (2012) 6.27
Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med (2014) 5.88
A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol (2004) 5.67
Comparative effectiveness of revascularization strategies. N Engl J Med (2012) 5.49
Bivalirudin for patients with acute coronary syndromes. N Engl J Med (2006) 5.49
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med (2012) 4.47
Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol (2012) 4.29
Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet (2012) 4.02
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol (2004) 3.67
Long-term outcome of percutaneous coronary intervention for chronic total occlusions. JACC Cardiovasc Interv (2011) 3.38
Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37
TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem (2009) 3.29
Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). J Am Coll Cardiol (2012) 3.29
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation (2004) 3.23
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA (2007) 3.07
Multiple testing, cumulative radiation dose, and clinical indications in patients undergoing myocardial perfusion imaging. JAMA (2010) 2.97
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med (2015) 2.97
Lack of association between migraine headache and patent foramen ovale: results of a case-control study. Circulation (2010) 2.88
Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors. J Am Coll Cardiol (2012) 2.85
The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol (2004) 2.78
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA (2008) 2.59
A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol (2005) 2.56
Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results of the PARTNER (Placement of Aortic Transcatheter Valves) trial (Cohort A). J Am Coll Cardiol (2012) 2.56
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol (2008) 2.54
Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation (2002) 2.53
Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation (2009) 2.47
Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol (2005) 2.42
Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation (2009) 2.40
A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis. JACC Cardiovasc Interv (2009) 2.30
Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography. JACC Cardiovasc Interv (2009) 2.29
Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation (2004) 2.29
The reporting of blinding in physical medicine and rehabilitation randomized controlled trials: a systematic review. J Rehabil Med (2013) 2.20
Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol (2004) 2.20
Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol (2005) 2.19
Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA (2006) 2.16
Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol (2007) 2.14
Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. JACC Cardiovasc Interv (2009) 2.12
Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revascularization. J Am Coll Cardiol (2006) 2.12
Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J (2011) 2.11
The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. J Invasive Cardiol (2010) 2.10
Blood pressure excursions below the cerebral autoregulation threshold during cardiac surgery are associated with acute kidney injury. Crit Care Med (2013) 2.09
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ (2008) 2.09
The impact of frailty status on survival after transcatheter aortic valve replacement in older adults with severe aortic stenosis: a single-center experience. JACC Cardiovasc Interv (2012) 2.08
Predicting the limits of cerebral autoregulation during cardiopulmonary bypass. Anesth Analg (2011) 2.07
Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv (2003) 2.06
Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial. J Am Coll Cardiol (2004) 2.05
Cause of death with bare metal and sirolimus-eluting stents. Eur Heart J (2006) 2.04
Effect of endothelial shear stress on the progression of coronary artery disease, vascular remodeling, and in-stent restenosis in humans: in vivo 6-month follow-up study. Circulation (2003) 2.04
Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA (2006) 2.03
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg (2012) 1.99